Kento Kato

Kento Kato

Auto-generated profile, based on publicly available information

Kento Kato

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 March 2018 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KTKazuki Takasaki
Kazuki Takasaki
MMMorikazu Miyamoto
Morikazu Miyamoto
MTMasashi Takano
Masashi Takano
HSHiroaki Soyama
Hiroaki Soyama
TATadashi Aoyama
Tadashi Aoyama
KFKenichi Furuya
Kenichi Furuya


1 October 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
HHH. Hasegawa
H. Hasegawa
HTHiroya Taniguchi
Hiroya Taniguchi
TKT. Kato
T. Kato
SFSatoshi Fujii
Satoshi Fujii
HEHiromichi Ebi
Hiromichi Ebi
TYT. Yoshino
T. Yoshino
FMS-like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis, and FLT3-associated molecular alterations are an established predictor for the treatment with FLT3 inhibitors in acute myeloid leukemia. However, the oncogenic role of FLT3 amplification (amp) in patients (pts) with metastatic colorectal cancer (mCRC) has not yet been well established. Tumor tissue samples from 2,329 mCRC pts were sequenced using next-generation sequencing (NGS) with Oncomine Comprehensive Assay in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Clinicopathological features, co-altered genes, prognosis and regorafenib efficacy on FLT3 amp (defined as copy number ≥ 7.0) vs. non-FLT3 amp mCRC were investigated. Between Apr 2015 and Jun 2018, a total of 85 pts (3.6%) with mCRC with FLT3 amp were observed. There were no clear differences in baseline characteristics between pts with or without FLT3 amp. The enrichment of TP53 mutation in FLT3 amp mCRC was observed more frequently than non-FLT3 amp (74.1% vs. 64.7%, P = 0.08), but RAS mutation frequency was similar in both (48.2% vs. 42.8%, P = 0.31). In contrast, activating alterations in BRAF (1.1% vs. 7.1%, P = 0.053) and PIK3CA (1.1% vs 7.0%, P = 0.03) mutations were both less frequent in FLT3 amp vs. non-FLT3 amp mCRC. Median OS from 1st-line chemotherapy in FLT3 amp mCRC was significantly shorter than those in non-FLT3 amp (30.2 vs. 43.4 months, P = 0.002). Furthermore, in 20 pts receiving regorafenib, a multikinase inhibitor with a mild inhibitory activity of FLT3, the disease control rate (DCR) was higher in FLT3 amp mCRC pts (n = 7) compared with non-FLT3 amp (57.1% vs. 23.0 %, P = 0.13). FLT3 amp was associated with a significantly worse survival and a higher DCR from regorafenib, suggesting it has a distinct oncogenic role in mCRC. Further investigation of the oncogenic role of FLT3 amp in mCRC is warranted in clinical trials. UMIN000016344. SCRUM-Japan. 17 SCRUM-Japan Collaborating Pharmaceutical Companies, AMED, NCC. H. Taniguchi: Research grant / Funding (self): Takeda; Advisory / Consultancy: Chugai; Advisory / Consultancy: Taiho. T. Kato: Honoraria (self): Chugai Pharmaceutical; Advisory / Consultancy: Takeda; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Yakult Honsya. S. Yuki: Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bayer Yakuhin; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Pharma International; Speaker Bureau / Expert testimony: Daiichi Sankyo; Speaker Bureau / Expert testimony: Takeda Pharmaceutical; Speaker Bureau / Expert testimony: Eli Lilly Japan; Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Biopharma. T. Masuishi: Honoraria (self): Eli Lilly; Honoraria (self): Chugai Pharma; Honoraria (self): Merck Serono; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Yakult Honsya. K. Kato: Research grant / Funding (self): Shionogi; Research grant / Funding (self): Ono Pharmaceutical; Research grant / Funding (self): Merck Serono. N. Izawa: Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: Sanofi; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Bristol-Myers; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Serono. T. Moriwaki: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): Eisai; Speaker Bureau / Expert testimony: Chugai Pharma; Speaker Bureau / Expert testimony: Yakult Honsha; Speaker Bureau / Expert testimony: Merck Serono; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Liliy Japan; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Ono Pharmaceutical. Y. Kagawa: Speaker Bureau / Expert testimony: Chugai; Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Sanofi; Speaker Bureau / Expert testimony: Taiho. W. Okamoto: Research grant / Funding (institution): MSD. Y. Nakamura: Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Taiho Pharmaceutical. K. Yamazaki: Honoraria (self): Daiichi Sankyo; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Eli Lilly; Honoraria (self): Merck Serono; Honoraria (self), Research grant / Funding (institution): Taiho Pharma; Honoraria (self): Bayer Yakuhin. T. Yoshino: Research grant / Funding (institution): Chugai pharma; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Sumitomo Dainippon pharma; Research grant / Funding (institution): Glaxo SmithKline. All other authors have declared no conflicts of interest.

9 April 2026 in Cancer Reports
Verified
Journal Article
Open access
THTaira Hada
Taira Hada
MMMorikazu Miyamoto
Morikazu Miyamoto
TETakahiro Einama
Takahiro Einama
SKSoichiro Kakimoto
Soichiro Kakimoto
MKMakiko Koga
Makiko Koga
MTMasashi Takano
Masashi Takano
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.

1 January 2026 in Obstetrics and Gynecology International
Verified
Journal Article
Open access
MTMinori Takada
Minori Takada
MMMorikazu Miyamoto
Morikazu Miyamoto
YKYohei Kaishi
Yohei Kaishi
YTYuna Tanaka
Yuna Tanaka
AIAkari Imauji
Akari Imauji
MTMasashi Takano
Masashi Takano
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.